<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908308</url>
  </required_header>
  <id_info>
    <org_study_id>TTM-2</org_study_id>
    <nct_id>NCT02908308</nct_id>
  </id_info>
  <brief_title>Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest</brief_title>
  <acronym>TTM-2</acronym>
  <official_title>Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest (TTM2) - A Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsingborgs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Skåne - Skånevård SUND</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trials Sweden, Forum South</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Integrated Biobank of Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsingborgs Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ILCOR guidelines recommend Target Temperature Management (TTM) to between 32°C and 36°C after
      out-of-hospital cardiac arrest, based on low quality evidence. In a previous trial, TTM at
      33°C did not confer a survival benefit or improved neurological function, compared to TTM at
      36°C. A lower target temperature might be beneficial compared with normothermia and early
      treatment of fever. Therefore the primary purpose of the TTM2-trial will be to study any
      differences in mortality, neurological function and quality of life between a target
      temperature of 33°C and standard care avoiding fever.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TTM2 trial is a continuation of the collaboration that resulted in the previous Targeted
      Temperature Management after out-of-hospital cardiac arrest trial (hereafter: TTM1). With its
      planned size with it will supersede the TTM1 trial as the largest trial on temperature
      management as a post-cardiac arrest treatment.

      The TTM1 trial (NCT01020916) was a multicenter, multinational, outcome assessor-blinded,
      parallel group, randomised clinical trial comparing two strict target temperature regimens of
      33°C and 36°C in adult patients, who have sustained return of spontaneous circulation and are
      unconscious after out-of-hospital cardiac arrest, when admitted to hospital. The trial did
      not demonstrate any difference in survival until end of trial (Hazard Ratio with a point
      estimate in favour of 36°C of 1.06 (95% confidence interval 0.89-1.28; P=0.51) or neurologic
      function at six months after the arrest, measured with CPC and mRS.

      The planned study is a international, multicenter, parallel group, non-commerical,
      randomized, superiority trial in which a target temperature om 33°C after cardiac arrest will
      be compared to normothermia and early treatment of fever.

      Patients eligible for inclusion will be unconscious adult patients with OHCA of a presumed
      cardiac cause with stable return of spontaneous circulation. Randomization will be performed
      by a physician in the emergency department, in the angiography suite or in the intensive care
      unit via web-based application using permuted blocks with varying sizes, stratified by site.
      Due to the nature of the intervention, health care staff will not be blinded to the
      intervention. However, the physicians who will assess outcomes will be blinded to temperature
      allocation, as will those who perform prognostication.

      The intervention period will commence at the time of randomization. Cooling in the
      hypothermia group will achieved by means of cold fluids and state-of-the-art cooling devices
      (intravascular or body-surface applied closed loop systems). The initial aim will be to
      achieve a body temperature of 33.0°C. When this has been achieved, the target temperature
      will be 33°C until 28 hours after randomisation. When 28 hours have passed, gradual rewarming
      at a rate of 1/3°C per hour will commence, this will allow 12 hours for rewarming.

      In the normothermia arm the aim will be to avoid a temperature greater than or equal to
      37.8°C using conservative measures. If a single temperature of 37.8° or greater is measured,
      active cooling with a device should be initiated and maintained until 40 hours after
      randomization.

      All subjects will be sedated, mechanically ventilated and hemodynamically supported
      throughout the intervention period of 40 hours. Subjects in both arms who remain comatose
      after 40h should be kept at a normothermic level (36.5 - 37.7°C) until 72h after
      randomization and active warming should be avoided.

      Subjects who remain unconscious four days after randomization will be assessed according to a
      conservative protocol based on the European Resuscitation Council's recommendations for
      withdrawal of life sustaining therapies.

      Follow up will be performed at:

      1 month (face-to-face or telephone), Assessment according to the modified Rankin scale (mRS)

      6 moths (face-to-face), Assessment according to the mRS-scale. Assessment of health-related
      quality of life using EQ5D-5L.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The clinical team responsible for the participant (physicians, nurses and others) and involved with direct patient care will not be blinded to allocation group due to the inherent difficulty in blinding the intervention and as temperature is a vital sign required for clinical care. Measures will be taken to ensure that the information about allocation will not disseminate beyond the immediate group of caregivers responsible for patient care. A blinded physician will evaluate the patient at 96 hours after randomisation and make a statement on neurological prognosis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>180 days</time_frame>
    <description>Landmark mortality at 180 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival until end of the trial</measure>
    <time_frame>180 days after randmomization of the last patient</time_frame>
    <description>Mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Poor functional outcome</measure>
    <time_frame>180 days</time_frame>
    <description>Assessed using the modified Rankin Scale (mRS), with a score of 4-6 being a poor outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>180 days</time_frame>
    <description>Health-related Quality of Life (EQ5-D) -VAS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive outside hospital</measure>
    <time_frame>180 days.</time_frame>
    <description>Number of days alive within 180 days from initial hospital discharge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1900</enrollment>
  <condition>Out-of-hospital Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Normothermia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Targeted temperature management to 33°C for up to 28h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted temperature management to 33°C</intervention_name>
    <description>Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.</description>
    <arm_group_label>Hypothermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard care with early treatment of fever</intervention_name>
    <description>Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C</description>
    <arm_group_label>Normothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out-of-hospital cardiac arrest

          -  Presumed cardiac cause of cardiac arrest

          -  Unconscious with a FOUR-score &lt;M4 (not obeying verbal commands)

          -  Stable return of spontaneous circulation (20 min)

          -  Eligible for intensive care treatment without restrictions

          -  Inclusion within 180 minutes of ROSC

        Exclusion Criteria:

          -  Unwitnessed cardiac arrest with an initial rhythm of asystole

          -  Temperature on admission &lt;30°C.

          -  On ECMO prior to ROSC

          -  Obvious or suspected pregnancy

          -  Intracranial bleeding

          -  On ECMO prior to ROSC

          -  Severe chronic obstructive pulmonary disorder (COPD) with long-term home oxygen
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niklas Nielsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsingborgs lasarett, Region Skåne, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Friberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Cronberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Hovdenes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matt P Wise, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Wales, Cardiff, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clifton W Callaway, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh, Pittsburgh, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Storm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University Medicine, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Cariou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Paris Descartes, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Erlinge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Rylander, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josef Dankiewicz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skåne University Hospital, Lund</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauro Oddo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Lausanne, Lausanne, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manoj Saxena, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute for Global Health, Sydney, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Nordberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Södersjukhuset, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabio Taccone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Erasme, Brussles, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Pelosi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Martino University Hospital, Genoa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Ioannidis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innsbruck University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Belholavek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prague University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena Levin, MSc</last_name>
    <phone>+4646171000</phone>
    <email>ttm2@ttm2trial.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josef Dankiewicz, MD, PhD</last_name>
    <phone>+4646171000</phone>
    <email>ttm2@ttm2trial.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ondrej Smid, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ondrej Smid, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iole Brunetti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Iole Brunetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeuwarden Hospital</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kuiper, MD, PhD</last_name>
      <email>mi.kuiper@wxs.nl</email>
    </contact>
    <investigator>
      <last_name>Michael Kuiper, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital - Lund</name>
      <address>
        <city>Lund</city>
        <state>Skåne</state>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Borgquist, MD, PhD</last_name>
      <email>ola.borgquist@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital - Malmö</name>
      <address>
        <city>Malmö</city>
        <state>Skåne</state>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Düring, MD</last_name>
      <email>joachim.during@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Rylander, MD, PhD</last_name>
      <email>christian.rylander@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Christian Rylander, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders Thorén, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsingborgs Hospital</name>
      <address>
        <city>Helsingborg</city>
        <zip>251 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Annborn, MD, PhD</last_name>
      <email>martin.annborn@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauro Oddo, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Mauro Oddo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Wise, MD, DPhil</last_name>
      <email>mattwise@doctors.org.uk</email>
    </contact>
    <investigator>
      <last_name>Matthew Wise, MD, DPhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Luxembourg</country>
  </removed_countries>
  <link>
    <url>http://ttm2trial.org</url>
    <description>Trial official webpage</description>
  </link>
  <reference>
    <citation>Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Køber L, Langørgen J, Lilja G, Møller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H; TTM Trial Investigators. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013 Dec 5;369(23):2197-206. doi: 10.1056/NEJMoa1310519. Epub 2013 Nov 17.</citation>
    <PMID>24237006</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsingborgs Hospital</investigator_affiliation>
    <investigator_full_name>Niklas Nielsen</investigator_full_name>
    <investigator_title>MD, PhD, Associate professor</investigator_title>
  </responsible_party>
  <keyword>Induced hypothermia</keyword>
  <keyword>Mild induced hypothermia</keyword>
  <keyword>Therapeutic hypothermia</keyword>
  <keyword>Cardiac arrest</keyword>
  <keyword>Out-of-hospital cardiac arrest</keyword>
  <keyword>Mortality</keyword>
  <keyword>Neurological function</keyword>
  <keyword>Randomised clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

